+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years - 49Years
All Genders
ID07229248

Comparing Drug Coated Balloon and Drug Eluting Stent in Young Adults Under 50 with STEMI A Randomized Trial at NICVD Karachi to Improve Heart Attack Treatment

Led by National Institute of Cardiovascular Diseases, Pakistan · Updated on 2025-11-14

496

Participants Needed

1

Research Sites

1 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of drug-coated balloons DCB compared to drug-eluting stents DES in young adults under 50 years old who have experienced ST Elevation Myocardial Infarction STEMI. This randomized controlled trial aims to determine if DCBs, which do not leave a permanent implant, can reduce risks associated with stents such as restenosis, thrombosis, and the need for prolonged dual antiplatelet therapy. The study is particularly important due to the high rate of STEMI in young adults in South Asia, especially at the National Institute of Cardiovascular Diseases NICVD in Karachi. The trial enrolls 496 patients randomized equally to receive either a paclitaxel-coated balloon DCB inflated for 30 seconds or a standard second-generation drug-eluting stent DES during primary percutaneous coronary intervention PCI. A pilot phase with 50 patients will first assess safety outcomes like abrupt vessel closure and bailout stenting. Participants in both groups receive ticagrelor twice daily for one month, followed by continued dual antiplatelet therapy. An intravascular ultrasound substudy will evaluate vessel remodeling and late lumen loss in 100 patients treated with DCB at baseline and six months. Participants will be monitored through clinical visits and phone follow-ups at 14 days, 30 days, 3, 6, and 12 months after the procedure. Researchers will assess outcomes including vessel-oriented cardiac events, bleeding, blood flow quality, residual narrowing, and need for additional stenting. The main goal is to compare one-year vessel-oriented composite endpoints such as cardiovascular or all-cause death, heart attack in the treated vessel, or repeat procedures. Safety and data quality are overseen by independent boards, and the total study duration per participant is 12 months.

CONDITIONS

Brief Title

DCB vs. DES in Young STEMI Patients: The DCB-STEMI Trial

Research Team

A

Abdul Hakeem, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here